{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-006522","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2024-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.144615+00:00","generated_at":"2026-05-31T03:49:16.406099+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aethlon receives ethics approval for Hemopurifier cancer trial in India; enrollment targeted Q4 2024","bullets":["Medanta Institutional Ethics Committee approved safety, feasibility, dose-finding trial of Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.","Trial at Medanta Medicity Hospital, Gurugram, India; Dr. Ashok K. Vaid and Dr. Puneet Sodhi as investigators.","Patient recruitment expected Q4 2024; primary endpoint is safety, with exploratory EV reduction analyses.","This adds to prior Australian ethics approvals and DCGI No Objection Certificate for the oncology trial.","Hemopurifier designed to remove tumor-derived extracellular vesicles that may drive resistance to PD-1 inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-006522","json":"https://secwatch.observer/filing/0001683168-24-006522.json","markdown":"https://secwatch.observer/filing/0001683168-24-006522.md","text":"https://secwatch.observer/filing/0001683168-24-006522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316824006522/0001683168-24-006522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316824006522/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:49:16.406099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}